Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin
Open Access
- 27 June 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 3 (1), 1-9
- https://doi.org/10.1007/s13300-012-0008-5
Abstract
The optimal stage for dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in the course of type 2 diabetes mellitus (T2DM) is still under discussion, with often a perception that treatment with these agents may be less beneficial with increasing disease progression, due to loss of beta-cell function, and with increasing insulin resistance (IR), where beta-cell function is less prominent. This work, therefore, aimed to assess the impact of such factors on the efficacy of the DPP-4 inhibitor, vildagliptin, in add-on therapy to metformin.Keywords
This publication has 35 references indexed in Scilit:
- Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trialDiabetes, Obesity and Metabolism, 2011
- LinagliptinDrugs, 2011
- Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studiesVascular Health and Risk Management, 2011
- VildagliptinDrugs, 2010
- The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering ActionDiabetes, 2010
- SitagliptinDrugs, 2010
- SaxagliptinDrugs, 2009
- Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??MellitusClinical Pharmacokinetics, 2007
- Estimation of Glomerular Filtration Rate in Diabetic SubjectsDiabetes Care, 2005
- The incretin concept todayDiabetologia, 1979